Publications by authors named "Mireia Resina-Salles"
Article Synopsis
- The study investigates how disease-modifying therapies, specifically anti-CD20 treatments and sphingosine 1-phosphate receptor modulators (S1PRM), affect immune responses to SARS-CoV-2 vaccines in patients with multiple sclerosis (MS) and other autoimmune diseases.
- Researchers enrolled 457 patients and measured both humoral (antibody) and cellular (T-cell) immune responses before and after vaccination, finding that responses varied based on treatment type and duration.
- Results indicate that while anti-CD20 and S1PRM treatments can reduce antibody responses, anti-CD20 patients may still generate T-cell responses even without detectable antibodies, highlighting the complexities of vaccine response in these populations.
Humoral and Cellular Responses to SARS-CoV-2 in Convalescent COVID-19 Patients With Multiple Sclerosis.
Neurol Neuroimmunol Neuroinflamm
March 2022
Background And Objectives: Information about humoral and cellular responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and antibody persistence in convalescent (COVID-19) patients with multiple sclerosis (PwMS) is scarce. The objectives of this study were to investigate factors influencing humoral and cellular responses to SARS-CoV-2 and its persistence in convalescent COVID-19 PwMS.
Methods: This is a retrospective study of confirmed COVID-19 convalescent PwMS identified between February 2020 and May 2021 by SARS-CoV-2 antibody testing.
Background And Purpose: Information regarding multiple sclerosis (MS) patients with the 2019 novel coronavirus disease (COVID-19) is scarce. The study objective was to describe the incidence and characteristics of MS patients with COVID-19, to identify susceptibility and severity risk factors and to assess the proportion of positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serologies according to disease-modifying treatments.
Methods: This was a retrospective study of an MS cohort analysing data collected between February and May 2020.